Navigation Links
Savara Pharmaceuticals Initiates Phase 2 Clinical Trial of AeroVanc for MRSA Lung Infection in Cystic Fibrosis Patients
Date:4/18/2013

AUSTIN, Texas, April 18, 2013 /PRNewswire/ --Savara Pharmaceuticals announced today that the first patient has started study drug treatment in a Phase 2 clinical trial evaluating the safety and efficacy of AeroVanc for the treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in cystic fibrosis (CF) patients. AeroVanc is the first inhaled antibiotic being developed to address the growing population of MRSA lung-infected CF patients.

Persistent MRSA lung infection in CF patients has been associated with increased use of intravenous (IV) antibiotics, increased hospitalizations, faster decline of lung function, as well as shortened life-expectancy. Persistent MRSA lung infection in CF patients is difficult to eradicate or manage using oral or IV antibiotics, and there is no standard of care to manage the infection in CF patients. IV vancomycin is the antibiotic of choice for acute exacerbations of MRSA lung infections in CF patients, but the burden related to IV administration, as well as poor penetration of vancomycin into the lungs and systemic toxicities, limit its use in a chronic setting. In contrast to the established treatment of Pseudomonas aeruginosa lung infection with inhaled antibiotics, there is no FDA-approved inhaled antibiotic treatment available for MRSA lung infection.

Savara's Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study in 80 CF patients at 22 CF centers nationwide. Patients will receive either 32 mg or 64 mg doses of AeroVanc or a corresponding placebo twice daily for 28 days. The primary objective of the study is to evaluate the efficacy of AeroVanc in reducing the quantity of MRSA colony forming units in the sputum cultures. The secondary objectives include evaluation of the efficacy of AeroVanc in improving lung function, reducing respiratory symptoms reported by the patients, and reducing the use of other antibiotics. Study results are expected in the first quarter of 2014.

"We are encouraged by the recent FDA approval of Novartis' dry-powder TOBI Podhaler for Pseudomonas aeruginosa infections in CF patients. An inhaled dry powder form of vancomycin for MRSA infection will be a logical addition to this and other treatment options available for CF patients," said Rob Neville , CEO of Savara Pharmaceuticals. "We are further encouraged by the strong interest and support of key opinion leaders, and the feedback that AeroVanc is exactly what the CF care community has been waiting for."  

Details of the AeroVanc Phase 2 study can be found at www.clinicaltrials.gov (study identifier NCT01746095).

About AeroVanc

Intravenous vancomycin is the antibiotic of choice for MRSA-related bronchopneumonia, however, the burden of IV administration, poor penetration into the lungs and systemic toxicities limit its use in a chronic setting. AeroVanc (vancomycin hydrochloride inhalation powder) is a proprietary inhaled dry powder form of vancomycin in a capsule-based device designed for convenient self-administration. By targeting vancomycin directly to the lungs, AeroVanc is expected to improve clinical efficacy and reduce side effects due to systemic drug exposure.

About Cystic Fibrosis

Cystic fibrosis is a life-shortening genetic disease characterized by thick, sticky mucus in the lungs and frequent lung infections, which result in loss of lung function. As the disease progresses, the lungs of CF patients are typically infected with bacteria that are difficult to eradicate. Physicians have been using nebulized antibiotics to treat these infections and have sought new options for treatment in the chronic care setting. The first successful reformulation of an antibiotic into dry powder inhaled therapy is the recently FDA-approved TOBI Podhaler (tobramycin inhalation powder) for Pseudomonas aeruginosa infections in CF patients. Infection by MRSA has become increasingly common with a prevalence of almost 30 percent of the estimated 30,000 CF patients in the U.S. 

About Savara Pharmaceuticals

Savara Pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. The company's lead product, AeroVanc, is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis. Savara receives funding for development of AeroVanc from the National Heart, Lung and Blood Institute of the National Institutes of Health under Award Number R44HL112393. The award spans 30 months and is subject to continued progression of the AeroVanc program. For more information about the company, please visit www.savarapharma.com.


'/>"/>
SOURCE Savara Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Tech Coast Angels Contributes More Than $3 Million to $16 Million Savara Pharmaceuticals Series B
2. Savara Pharmaceuticals Announces Formation of Clinical Advisory Board
3. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
4. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
5. Vanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
6. Inovio Pharmaceuticals Recognized With "Best Therapeutic Vaccine" and "Best Early Stage Biotech" Awards at World Vaccine Congress 2013
7. Oramed Pharmaceuticals Chosen to Present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria; April 18-20, 2013
8. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
9. JHP Pharmaceuticals to Produce Supplies of Biologic Drug Product for Late-Phase Clinical Trials
10. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
11. Omthera Pharmaceuticals, Inc. Announces Closing of Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... The campaign aims to ensure 2,50,532 ... reach the milestone of their 5 th birthday   --> ... between the ages of 2 - 5 years reach the ... campaign aims to ensure 2,50,532 children ... of their 5 th birthday   India , ...
(Date:2/9/2016)...  Misonix, Inc. (NASDAQ: MSON ), an ... markets innovative therapeutic ultrasonic products for spine surgery, ... surgery and other surgical applications, today announced financial ... half of fiscal year 2016 ended December 31, ... --> Highlights for the second quarter and ...
(Date:2/9/2016)... YORK, Pa., Feb. 9, 2016  Unilife Corporation ("Unilife" or "Company") ... of injectable drug delivery systems, today announced its financial results for ... 2015). ... Revenue for the ... million in the same period last year.  Cash receipts from customers ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced on Wednesday that ... an emergency medicine professional association, to support the organization's newly established physician group ... of Emergency Medicine, or AAEM, seeks to empower emergency physicians to control their ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... Emergency rooms ... harder to find. Unfortunately, this can leave patients with dental emergencies at risk of ... is now offering emergency dental care. , Common dental emergencies include:, ...
(Date:2/10/2016)... ... 10, 2016 , ... Dr. Jessica Barron, of Barron Family Dental in ... patients and families in the North Metro Denver area. The new dental practice focuses ... dentistry, and all in the most relaxing environment. , While some dental visits can ...
(Date:2/10/2016)... ... February 10, 2016 , ... United Benefit Advisors ... the latest addition to its growing list of Partner Firms. S.S. Nesbitt ... from Orlando to Huntsville and in between. , Harnessing the experience and insights ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience ... across their network of laboratory service centers across the country. Launched in April of ... in the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. ...
Breaking Medicine News(10 mins):